Form 4: Voyager Therapeutics Director, Grace Colon, Acquires 24,000 Stock Options

Director Grace Colon acquired 24,000 stock options in Voyager Therapeutics, Inc. on June 5, 2024, according to a Form 4 filing.

Summary

• Grace Colon, a director of Voyager Therapeutics, Inc., acquired 24,000 stock options on June 5, 2024.
• The options have an exercise price of $8.70.
• The options were granted under the company's 2015 Stock Option and Incentive Plan, as part of the director compensation policy.
• The options vest upon the earlier of one year from the grant date or the date of the next annual meeting of stockholders, contingent on continued service as a director.
• The options expire on June 5, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is a common practice. There's no indication of significant positive or negative implications.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, as the value of the options increases with the company's stock price.

Key Dates